Coya Therapeutics (NASDAQ:COYA) Posts Earnings Results, Beats Estimates By $0.08 EPS

Coya Therapeutics (NASDAQ:COYA) issued its quarterly earnings data on Tuesday. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.08, Zacks reports. Coya Therapeutics had a negative net margin of 266.10% and a negative return on equity of 55.86%.

Coya Therapeutics Trading Up 0.6%

Shares of NASDAQ COYA traded up $0.03 during mid-day trading on Tuesday, hitting $4.67. The company had a trading volume of 50,538 shares, compared to its average volume of 193,531. Coya Therapeutics has a 1 year low of $3.71 and a 1 year high of $7.75. The company has a market capitalization of $109.56 million, a price-to-earnings ratio of -4.11 and a beta of 0.61. The stock’s 50-day moving average price is $4.86 and its 200-day moving average price is $4.67.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on COYA shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Coya Therapeutics in a research report on Friday, July 17th. Chardan Capital reissued a “buy” rating and issued a $14.00 price target on shares of Coya Therapeutics in a report on Friday, June 12th. Roth Capital initiated coverage on shares of Coya Therapeutics in a report on Friday, June 5th. They set a “buy” rating and a $12.00 price objective for the company. Finally, Wall Street Zen cut shares of Coya Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $15.33.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of COYA. Alyeska Investment Group L.P. bought a new position in shares of Coya Therapeutics in the fourth quarter worth $4,640,000. AWM Investment Company Inc. purchased a new stake in shares of Coya Therapeutics during the 4th quarter valued at $4,205,000. Private Management Group Inc. purchased a new stake in Coya Therapeutics during the fourth quarter valued at about $1,626,000. Marshall Wace LLP increased its position in shares of Coya Therapeutics by 438.8% during the 4th quarter. Marshall Wace LLP now owns 225,358 shares of the company’s stock valued at $1,307,000 after purchasing an additional 183,533 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of Coya Therapeutics by 26.2% during the 4th quarter. Geode Capital Management LLC now owns 197,988 shares of the company’s stock valued at $1,149,000 after buying an additional 41,143 shares in the last quarter. 39.75% of the stock is owned by institutional investors.

About Coya Therapeutics

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.